Sponsors of testosterone products may have more difficulty promoting their products as FDA’s new proposed labeling removes many of the signs and symptoms of low testosterone that sponsors have used to describe the condition and benefits of treatment to the general public.
Testosterone Label Changes Could Make Advertising More Challenging
FDA proposal obtained by “The Pink Sheet” DAILY eliminates language describing symptoms of low testosterone.
More from United States
• By
Experts say PBMs should become familiar with transparency rules and prepare to release data, although more legal wrangling could occur.
• By
Optum Rx, one of the largest PBMs in the US, declared it was the “first comprehensive, transparent pharmacy services company” after announcing several consumer-friendly changes.
• By
FDA Commissioner Martin Makary was sworn in Friday and knew of the plan that ultimately lead to CBER director Peter Marks' resignation on 28 March.
• By
In his resignation letter, the CBER director said he was willing to work with HHS Secretary Robert F. Kennedy Jr. to address concerns about vaccine safety, but "it has become clear that truth and transparency are not desired by the secretary."